EMEA-003030-PIP02-21 - paediatric investigation plan

Yellow fever virus, strain vYF-247

Key facts

• Active Substance:
  Yellow fever virus, strain vYF-247
• Therapeutic area:
  Vaccines
• Decision number:
  P/0425/2022
• PIP number:
  EMEA-003030-PIP02-21
• Pharmaceutical form(s):
  Powder and solvent for solution for injection
• Condition(s) / indication(s):
  Prevention of Yellow Fever disease
• Route(s) of administration:
  • Intramuscular use
  • Subcutaneous use
• Contact for public enquiries:

  Sanofi Pasteur

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  28/10/2022

Decision

P/0425/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for yellow fever virus, strain vYF-247 (EMEA-003030-PIP02-21)

AdoptedReference Number: EMA/825331/2022